Operating as a clinical-stage biopharmaceutical enterprise, Synlogic, Inc. is dedicated to the creation and progression of synthetic biotic therapeutics aimed at addressing metabolic and immunological conditions across the United States. Its robust portfolio features multiple drug candidates: SYNB1618 and SYNB1934, both non-systemically absorbed and orally administered, are progressing through Phase II clinical trials for phenylketonuria. Another oral, non-systemic agent, SYNB1353, is designed to treat homocystinuria. Furthermore, SYNB8802, an orally taken, non-systemic compound, is currently in Phase I trials for managing enteric hyperoxaluria. Beyond oral treatments, the company is also developing SYNB1891, an intratumorally delivered synthetic biotic medicine undergoing Phase I investigation for solid tumors and lymphoma. Synlogic, Inc. has established partnerships with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc., and its main office is located in Cambridge, Massachusetts.
